Keyword: Themis Bioscience
There aren’t any vaccines against the painful viral infection chikungunya, but with new phase 2 results, Themis is one step closer to changing that.
Right on the heels of last week's deal in Lassa fever, CEPI has awarded IDT Biologika up to $36 million for MERS research.
Here is some other vaccine news of note for the week.
Merck and international agencies are preparing to roll out the experimental vaccine, hoping to stifle a new wave of cases that has killed 19 people.
PaxVax picked up the FDA's fast track tag for its chikungunya vaccine.
The five-year grant will support Inovio through phase 2 development of DNA vaccines against Lassa fever and MERS.
Experts say technology is advancing to develop vaccines faster at a time of increasing emerging disease outbreaks.
Amid a devastating outbreak in Nigeria, Themis plans to be first to test a Lassa fever vaccine in humans as early as this year.
The public-private vaccine coalition will support Themis' development of Lassa fever and MERS vaccines through phase 2.
An investment fund formed by J.P. Morgan and the Gates Foundation, Global Health Investment Fund led Themis' €10 million series C.